{"id":860669,"date":"2025-06-16T07:03:52","date_gmt":"2025-06-16T11:03:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/"},"modified":"2025-06-16T07:03:52","modified_gmt":"2025-06-16T11:03:52","slug":"helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/","title":{"rendered":"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device"},"content":{"rendered":"
\n

\n – CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161-<\/em>\n <\/p>\n

\n -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- <\/em>\n <\/p>\n

NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,\u00a0today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan.<\/p>\n

\u201cWith approvals now secured from five major commercial healthcare payers, we are making significant progress increasing MS patient access to the PoNS device,\u201d said Dane Andreeff, Helius President and Chief Executive Officer. \u201cImportantly, these out-of-network total lump sum reimbursement payments at over $19,000, reinforce the value of PoNS while strengthening and supporting our ongoing efforts to achieve broader reimbursement from CMS and coverage across the healthcare landscape.\u201d<\/p>\n

Depending on the individual\u2019s deductible and out-of-pocket costs, these claims may not result in an immediate PoNS Device sale.<\/p>\n

\n About the PoNS Device and PoNS Therapy<\/strong>\n <\/p>\n

The Portable Neuromodulation Stimulator (\u201cPoNS\u201d) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it\u2019s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.<\/p>\n

PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (\u201cmmTBI\u201d) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit\u00a0www.ponstherapy.com<\/a>.<\/p>\n

\n About Helius Medical Technologies, Inc.<\/strong>\n <\/p>\n

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain\u2019s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company\u2019s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS\u00ae<\/sup>\u00a0or Helius Medical Technologies, visit\u00a0www.heliusmedical.com<\/a>.<\/p>\n

\n Cautionary Disclaimer Statement<\/strong>\n <\/p>\n

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201cgoal,\u201d \u201caim\u201d and similar expressions. Such forward-looking statements include, among others, statements regarding commercial reimbursement of the PoNS Device and the uses and effectiveness of PoNS and PoNS Therapy.<\/p>\n

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include uncertainties associated with the Company\u2019s capital requirements to achieve its business objectives, availability of funds, the Company\u2019s ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company\u2019s ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company\u2019s ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov<\/a>\u00a0or www.sedar.com<\/a>.<\/p>\n

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.<\/p>\n

\n Investor Relations Contact<\/strong>\u00a0<\/p>\n

Philip Trip Taylor
Gilmartin Group
investorrelations@heliusmedical.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

– CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,\u00a0today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan. \u201cWith approvals now secured from five major commercial healthcare payers, we are making significant … <\/p>\n

Continue reading “Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860669","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHelius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,\u00a0today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan. \u201cWith approvals now secured from five major commercial healthcare payers, we are making significant … Continue reading "Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T11:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device\",\"datePublished\":\"2025-06-16T11:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/\"},\"wordCount\":919,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/\",\"name\":\"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=\",\"datePublished\":\"2025-06-16T11:03:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/","og_locale":"en_US","og_type":"article","og_title":"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device - Market Newsdesk","og_description":"– CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,\u00a0today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan. \u201cWith approvals now secured from five major commercial healthcare payers, we are making significant … Continue reading \"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-16T11:03:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device","datePublished":"2025-06-16T11:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/"},"wordCount":919,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/","name":"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=","datePublished":"2025-06-16T11:03:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODg3MyM2OTkxODIyIzIwODIwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-claim-authorization-by-cignahealth-for-its-portable-neuromodulation-stimulator-pons-device\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS\u00ae) Device"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860669"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}